在感染性肠炎的儿童随机对照试验和成人观察研究中对布拉氏酵母菌进行年龄分层评估
Age-stratified Evaluation Of Saccharomyces boulardii In A Pediatric Randomized Controlled Trial And Adult Observational Study of Infectious Enteritis.
摘要(中文译文)
感染性肠炎仍然是全球重要的健康负担，尤其在五岁以下儿童中。布拉氏酵母菌（Saccharomyces boulardii，S. boulardii）作为一种益生菌酵母，其在减少腹泻方面的作用已被广泛研究；然而，对其在不同年龄组间效果的直接比较仍然有限。本研究旨在评估并比较布拉氏酵母菌在儿童和成人感染性肠炎患者中的疗效与安全性。研究对186名急性腹泻儿童开展了双盲、随机、安慰剂对照试验，同时一项回顾性观察研究纳入了270名成人患者。所有参与者均接受标准补液治疗；干预组额外接受布拉氏酵母菌。主要结局为腹泻持续时间。次要结局包括排便频率、住院时间、复发率和不良事件。在儿童患者中，与安慰剂相比，布拉氏酵母菌显著缩短了腹泻持续时间（轮状病毒阳性病例为2.1天 vs. 3.9天）、住院时间（3.2天 vs. 4.8天）和排便频率（4.2次/天 vs. 6.7次/天）（均 p < 0.05）。在成人患者中，布拉氏酵母菌与较短的腹泻持续时间（2.7天 vs. 5.4天）、缩短的住院时间（3.6天 vs. 5.2天）、更高的症状缓解率（77.8% vs. 15.8%）和较低的复发率（8.1% vs. 21.7%；均 p < 0.01）相关。不良事件轻微，组间相当。布拉氏酵母菌似乎是感染性肠炎一种安全有效的辅助治疗，其临床结局存在年龄相关差异。布拉氏酵母菌似乎是儿童和成人感染性肠炎人群中一种安全有效的辅助治疗。在各队列内，观察到临床结局的改善，包括腹泻持续时间、住院和复发。儿童与成人队列之间观察到的差异为描述性结果，反映的是在不同研究设计下进行的独立分析；因此，未进行年龄组间的直接统计学比较。
Abstract
Infectious enteritis remains a significant global health burden, particularly among children under five years of age. Saccharomyces boulardii (S. boulardii), a probiotic yeast, has been widely studied for its role in reducing diarrhea; however, direct comparisons of its effects across age groups remain limited. This study aims to evaluate and compare the efficacy and safety of S. boulardii in pediatric and adult patients with infectious enteritis. A double-blind, randomized, placebo-controlled trial was conducted in 186 children with acute diarrhea, while a retrospective observational study included 270 adult patients. All participants received standard rehydration therapy; the intervention groups additionally received S. boulardii. The primary outcome was diarrhea duration. Secondary outcomes included stool frequency, length of hospital stay, recurrence rate, and adverse events. In pediatric patients, S. boulardii significantly reduced diarrhea duration (2.1 vs. 3.9 days in rotavirus-positive cases), hospital stay (3.2 vs. 4.8 days), and stool frequency (4.2 vs. 6.7 stools/day) compared to placebo (all p < 0.05). In adult patients, S. boulardii was associated with shorter diarrhea duration (2.7 vs. 5.4 days), reduced hospital stay (3.6 vs. 5.2 days), higher symptom resolution rates (77.8% vs. 15.8%), and lower recurrence (8.1% vs. 21.7%; all p < 0.01). Adverse events were mild and comparable between groups. S. boulardii appears to be a safe and effective adjunct therapy for infectious enteritis, with age-related differences in clinical outcomes. S. boulardii appears to be a safe and effective adjunct therapy for infectious enteritis in both pediatric and adult populations. Within each cohort, improvements were observed in clinical outcomes, including diarrhea duration, hospitalization, and recurrence. Observed differences between pediatric and adult cohorts are descriptive and reflect separate analyses conducted under different study designs; therefore, no direct statistical comparisons between age groups were performed.
如何引用
AMA
Yuanhai Lou, Qi Wang, Xiaojing Xing. Age-stratified Evaluation Of Saccharomyces boulardii In A Pediatric Randomized Controlled Trial And Adult Observational Study of Infectious Enteritis.. Journal of visualized experiments : JoVE. 2026; doi:10.3791/70695.
APA
Yuanhai Lou, Qi Wang, Xiaojing Xing (2026). Age-stratified Evaluation Of Saccharomyces boulardii In A Pediatric Randomized Controlled Trial And Adult Observational Study of Infectious Enteritis.. Journal of visualized experiments : JoVE. https://doi.org/10.3791/70695
GB/T 7714
Yuanhai Lou, Qi Wang, Xiaojing Xing. Age-stratified Evaluation Of Saccharomyces boulardii In A Pediatric Randomized Controlled Trial And Adult Observational Study of Infectious Enteritis.[J]. Journal of visualized experiments : JoVE, 2026 doi:10.3791/70695.
在 PubMed增强版 阅读全文
翻译全文 · AI 文献问答 · PDF 原文下载 · 引用导出